Cure My Disease

Don't miss your cure!

 Log in / Sign up

A Non-Opioid painkiller may cut opioid use after knee surgery

NCT ID NCT07796152

Symptom relief Sponsor: Endeavor Health Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 01, 2026 · Last updated Sep 03, 2026 · Updated 2 times

Summary

This trial tests whether adding suzetrigine, a non-opioid pain medicine, to standard care can reduce pain and opioid use after outpatient total knee replacement. About 100 participants will take suzetrigine before and for 14 days after surgery, alongside their usual pain medicines. They will track their pain and medication use daily for two weeks and again at day 30. The study compares their outcomes to those of similar patients receiving standard care alone.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Suzetrigine (Journavx), a non-opioid pain medicine, added to standard care pain medicines
What this could lead to
If it works, this could point toward a way to manage post-surgery pain with fewer opioids, potentially lowering the risk of opioid dependence.
What could go wrong
This is a small, single-site study, and results may not apply to all patients. Suzetrigine can cause side effects and is not suitable for people with certain liver or kidney problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * outpatient total knee arthroplasty (TKA) at Endeavor Health performed by orthopaedic surgeon Dr. Bashyal Exclusion Criteria: * Allergy to suzetrigine or any of its ingredients * Contraindication to suzetrigine (eg moderate to severe hepatic impairment, severe renal impairment) * Previous or current suzetrigine prescription * Use of a concomitant medication that is a strong CYP3A inhibitor * Patients unwilling to discontinue use of grapefruit or food and drink containing grapefruit while taking suzetrigine * Pregnant or lactating women * Women taking hormonal contraceptives containing progestins other than levonorgestrel and norethindrone must agree to use barrier contraception (eg condoms) or abstain from intercourse during the study or will be excluded from the study for safety reasons * Pre-operative peripheral nerve stimulation (PNS) system in place * Age \< 18 * Dementia or other mental issue that would interfere with accurate pain and medication reporting * Those unable to consent in English

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Knee arthroplasty, total are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Pain, Postoperative

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Knee arthroplasty, total Opioid consumption, postoperative Post operative pain, acute

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Endeavor Health, Skokie Hospital

    Skokie, Illinois, 60076, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.